Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty.
作者信息
Ko Darae, Pascual-Leone Alvaro, Shah Sachin J
机构信息
Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts.
Section of Cardiovascular Medicine, Boston Medical Center, Boston, Massachusetts.
出版信息
JAMA. 2024 Apr 2;331(13):1089-1090. doi: 10.1001/jama.2024.2991.
Abstract
摘要
相似文献
1
Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty.莱卡奈单抗在心血管疾病患者中的应用：不确定性带来的挑战。
JAMA. 2024 Apr 2;331(13):1089-1090. doi: 10.1001/jama.2024.2991.
2
Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis.用lecanemab进行单克隆治疗轻度阿尔茨海默病：一项系统评价和荟萃分析。
Ageing Res Rev. 2025 Feb;104:102620. doi: 10.1016/j.arr.2024.102620. Epub 2024 Dec 3.
3
Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.在轻度认知障碍和阿尔茨海默病患者中，比较 donanemab、lecanemab、aducanumab 和锂对认知功能的疗效、耐受性和可接受性：一项系统评价和网络荟萃分析。
Ageing Res Rev. 2024 Feb;94:102203. doi: 10.1016/j.arr.2024.102203. Epub 2024 Jan 20.
4
Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real-word study on aducanumab and lecanemab.在一家认知障碍三级中心，轻度认知障碍和早期阿尔茨海默病患者使用疾病修饰疗法的资格：一项关于阿杜卡努单抗和仑卡奈单抗的同步真实世界研究
Eur J Neurol. 2025 Jan;32(1):e16534. doi: 10.1111/ene.16534. Epub 2024 Nov 5.
5
Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center.在区域医疗中心的 71 例患者中应用 Lecanemab 的初步经验和教训。
J Prev Alzheimers Dis. 2024;11(6):1549-1562. doi: 10.14283/jpad.2024.159.
6
Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.多奈单抗、莱卡奈单抗、阿杜卡单抗、褪黑素及有氧运动对轻度认知障碍和轻度阿尔茨海默病认知功能短期影响的疗效、耐受性及可接受性比较：一项系统评价与网状Meta分析
J Alzheimers Dis. 2024;98(3):825-835. doi: 10.3233/JAD-230911.
7
Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease.Lecanemab：一种用于治疗早期阿尔茨海默病的人源化单克隆抗体。
Ann Pharmacother. 2024 Oct;58(10):1045-1053. doi: 10.1177/10600280231218253. Epub 2023 Dec 14.
8
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
9
Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease.仑卡奈单抗治疗早期阿尔茨海默病患者的成本效益分析
Neurology. 2024 Apr 9;102(7):e209218. doi: 10.1212/WNL.0000000000209218. Epub 2024 Mar 14.
10
Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.与患有阿尔茨海默病和轻度认知障碍的医疗保险受益人群相比，有资格参加阿杜卡奴单抗治疗阿尔茨海默病临床试验的参与者的代表性。
JAMA. 2021 Oct 26;326(16):1627-1629. doi: 10.1001/jama.2021.15286.
引用本文的文献
1
Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers.描述临床医生与患者关于lecanemab的沟通情况：一项对七个学术医疗中心临床医生的定性研究。
Alzheimers Dement (N Y). 2025 Aug 26;11(3):e70150. doi: 10.1002/trc2.70150. eCollection 2025 Jul-Sep.
2
Multimorbidity in dementia: Current perspectives and future challenges.痴呆症中的多重疾病：当前观点与未来挑战。
Alzheimers Dement. 2025 Aug;21(8):e70546. doi: 10.1002/alz.70546.
3
[Pharmacological developments in Alzheimer's disease].[阿尔茨海默病的药理学进展]
Aten Primaria. 2025 May;57(5):103281. doi: 10.1016/j.aprim.2025.103281. Epub 2025 Apr 24.
4
A qualitative study of people with Alzheimer's disease in a memory clinic considering lecanemab treatment.一项针对记忆门诊中考虑使用lecanemab治疗的阿尔茨海默病患者的定性研究。
J Alzheimers Dis. 2025 May;105(2):494-504. doi: 10.1177/13872877251329519. Epub 2025 Apr 10.
5
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics.用于早期阿尔茨海默病的莱卡奈单抗：法国记忆诊所联合会的合理使用建议
J Prev Alzheimers Dis. 2025 Apr;12(4):100094. doi: 10.1016/j.tjpad.2025.100094. Epub 2025 Feb 25.
6
Evaluating Lecanemab Eligibility for Patients in Skilled Nursing Facilities With Alzheimer Disease or Mild Cognitive Impairment.评估患有阿尔茨海默病或轻度认知障碍的熟练护理机构患者使用lecanemab的适用性。
J Am Med Dir Assoc. 2024 Nov;25(11):105192. doi: 10.1016/j.jamda.2024.105192. Epub 2024 Aug 6.
7
Challenges for emergency departments: Anti-amyloid therapy and amyloid-related imaging abnormalities in persons with dementia.急诊科面临的挑战：痴呆患者的抗淀粉样蛋白治疗及淀粉样蛋白相关影像异常
J Am Geriatr Soc. 2024 Dec;72(12):3945-3949. doi: 10.1111/jgs.19099. Epub 2024 Jul 22.
本文引用的文献
1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
2
Lecanemab: Appropriate Use Recommendations.仑卡奈单抗：合理使用建议。
J Prev Alzheimers Dis. 2023;10(3):362-377. doi: 10.14283/jpad.2023.30.
3
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.一名接受lecanemab治疗并因中风接受t-PA治疗的患者发生多处脑出血。
N Engl J Med. 2023 Feb 2;388(5):478-479. doi: 10.1056/NEJMc2215148. Epub 2023 Jan 4.
4
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
5
Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020.2010-2020 年新诊断心房颤动老年患者口服抗凝药物使用趋势。
JAMA Netw Open. 2022 Nov 1;5(11):e2242964. doi: 10.1001/jamanetworkopen.2022.42964.
Zotero 插件